{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:40:57Z","timestamp":1776058857827,"version":"3.50.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by persistent synovial inflammation, progressive cartilage destruction, and irreversible bone erosion. Although substantial progress has been made in identifying downstream inflammatory mediators, the upstream regulatory architecture governing immune imbalance in RA remains incompletely understood. Members of the interleukin-12 (IL-12) cytokine family are key regulators of T-cell differentiation and inflammatory amplification. Among them, IL-35 and IL-39 represent functionally opposing yet incompletely characterised cytokines with emerging relevance to RA pathogenesis. IL-35, predominantly produced by regulatory T and B cells, exerts immunosuppressive effects by inhibiting T helper 17 (Th17) responses, expanding regulatory lymphocyte populations, and modulating macrophage polarisation. Evidence suggests dysregulation of the IL-35 axis in RA, characterised by reduced systemic levels but relative synovial upregulation, possibly reflecting a compensatory response to persistent inflammation. In contrast, IL-39, derived from activated B cells and myeloid cells, promotes inflammatory cascades through STAT1\/STAT3 signalling. Circulating IL-39 levels correlate with disease activity and inflammatory biomarkers, supporting its potential role in sustaining immune activation. This mini-review synthesises current evidence on the divergent immunobiology of IL-35 and IL-39 in RA, evaluates their mechanistic pathways, and discusses their translational implications as biomarkers and therapeutic targets. By examining IL-35 alongside the relatively understudied cytokine IL-39, we highlight the added value of this pairing in clarifying their shared and distinct biological functions. We propose that disruption of regulatory\u2013inflammatory equilibrium within the IL-12 cytokine family provides a conceptual framework for understanding immune dysregulation in RA and may inform precision immunomodulatory strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1810466","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:41:30Z","timestamp":1776055290000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent roles of IL-35 and IL-39 in rheumatoid arthritis: restoring cytokine balance within the IL-12 family"],"prefix":"10.3389","volume":"17","author":[{"given":"Xingyan","family":"Ling","sequence":"first","affiliation":[{"name":"Scientific Research Section, The Third Affiliated Hospital of Gansu University of Chinese Medicine","place":["Baiyin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Respiratory Centre, The Third Affiliated Hospital of Gansu University of Chinese Medicine","place":["Baiyin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieliang","family":"Hu","sequence":"additional","affiliation":[{"name":"Joint Surgery, The First People\u2019s Hospital of Baiyin, The Third Affiliated Hospital of Gansu University of Chinese Medicine","place":["Baiyin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett D","family":"Hambly","sequence":"additional","affiliation":[{"name":"Scientific Research Section, The Third Affiliated Hospital of Gansu University of Chinese Medicine","place":["Baiyin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shisan","family":"Bao","sequence":"additional","affiliation":[{"name":"Scientific Research Section, The Third Affiliated Hospital of Gansu University of Chinese Medicine","place":["Baiyin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01169-7","article-title":"Management strategies in rheumatoid arthritis","volume":"20","author":"Konzett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.509","article-title":"Rheumatoid arthritis: pathogenesis and therapeutic advances","volume":"5","author":"Gao","year":"2024","journal-title":"MedComm (2020)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11926-025-01180-1","article-title":"T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease","volume":"27","author":"Chin","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867260","article-title":"The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis","volume":"13","author":"Cutolo","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114499","article-title":"T cell dysregulation in rheumatoid arthritis: recent advances and natural product interventions","volume":"153","author":"Hu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.06.010","article-title":"Innate immunity drives pathogenesis of rheumatoid arthritis","volume":"44","author":"Edilova","year":"2021","journal-title":"BioMed J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051529","article-title":"Rheumatoid factor: diagnostic and prognostic performance and therapeutic implications in rheumatoid arthritis","volume":"14","author":"Togashi","year":"2025","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1629759","article-title":"The role of IL-37 and IL-38 in rheumatoid arthritis, the potential clinical applications in precision medicine","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S474879","article-title":"Role of IL-1 family cytokines IL-36, IL-37, IL-38 in osteoarthritis and rheumatoid arthritis: a comprehensive review","volume":"17","author":"Xu","year":"2024","journal-title":"J Inflammation Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100263","article-title":"IL-12 family cytokines and autoimmune diseases: a potential therapeutic target","volume":"10","author":"Cui","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v11090772","article-title":"Immunoregulatory functions of the IL-12 family of cytokines in antiviral systems","volume":"11","author":"Guo","year":"2019","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00784-023-05484-3","article-title":"IL-39 and IL-35 gingival crevicular fluid levels in diabetic patients with generalized periodontitis","volume":"28","author":"Hassan","year":"2024","journal-title":"Clin Oral Investig"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2023.2165941","article-title":"Investigation of IL-35 and IL-39, new members of the IL-12 family, in different clinical presentations of brucellosis","volume":"52","author":"Ellergezen","year":"2023","journal-title":"Immunol Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13962","article-title":"Interleukin-35 regulates the balance of Th17 and Treg responses during the pathogenesis of connective tissue diseases","volume":"24","author":"Wang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093329","article-title":"Toll-like receptor signaling and immune regulatory lymphocytes in periodontal disease","volume":"21","author":"Gu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902739","article-title":"IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10","volume":"184","author":"Kochetkova","year":"2010","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"154076","DOI":"10.1016\/j.cyto.2017.06.003","article-title":"IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases","volume":"122","author":"Li","year":"2019","journal-title":"Cytokine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01095.x","article-title":"The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA)","volume":"119","author":"Kim","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6090081","article-title":"IL-23 and Th17 disease in inflammatory arthritis","volume":"6","author":"Yago","year":"2017","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/jir.2021.0147","article-title":"Interleukin-35: structure, function and its impact on immune-related diseases","volume":"41","author":"Ye","year":"2021","journal-title":"J Interferon Cytokine Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600446","article-title":"IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1\/M2 macrophage ratio in psoriasis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2018-000814","article-title":"Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity","volume":"67","author":"Li","year":"2019","journal-title":"J Investig Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107231","article-title":"Association of IL-35 expression and gene polymorphisms in rheumatoid arthritis","volume":"90","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132674","article-title":"Interleukin 35 synovial fluid levels are associated with disease activity of rheumatoid arthritis","volume":"10","author":"Senolt","year":"2015","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108330","article-title":"IL-35 promotes microglial M2 polarization in a rat model of diabetic neuropathic pain","volume":"685","author":"Jiang","year":"2020","journal-title":"Arch Biochem Biophys"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu528","article-title":"Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis","volume":"54","author":"Nakano","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4103\/err.err_37_18","article-title":"Role of interleukin-35 in rheumatoid arthritis pathogenesis and its relation to disease activity and joint damage","volume":"46","author":"Akl","year":"2019","journal-title":"Egyptian Rheumatol Rehabil"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020323","article-title":"Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment","volume":"10","author":"Bonek","year":"2021","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156969","article-title":"The role of IL-39 in autoimmune diseases: from general to immunopathogenesis","volume":"192","author":"Ahmadi","year":"2025","journal-title":"Cytokine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01235-x","article-title":"The IL-23p19\/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man","volume":"68","author":"Bridgewood","year":"2019","journal-title":"Inflammation Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201546095","article-title":"A novel IL-23p19\/Ebi3 (IL-39) cytokine mediates inflammation in lupus-like mice","volume":"46","author":"Wang","year":"2016","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242329","article-title":"Lack of evidence for expression and function of IL-39 in human immune cells","volume":"15","author":"Ecoeur","year":"2020","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.409","article-title":"Interleukin-39 is a novel cytokine associated with type 2 diabetes mellitus and positively correlated with body mass index","volume":"6","author":"Nussrat","year":"2023","journal-title":"Endocrinol Diabetes Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09432-x","article-title":"Increased synthesis and intestinal expression of IL-39 in patients with inflammatory bowel disease","volume":"72","author":"Fonseca-Camarillo","year":"2024","journal-title":"Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1236-y","article-title":"IL-39 acts as a friend to pancreatic cancer","volume":"36","author":"Manning","year":"2018","journal-title":"Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2023.110616","article-title":"Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosis","volume":"119","author":"Ying","year":"2023","journal-title":"Clin Biochem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.51248\/.v42i4.1866","article-title":"An assessment of serum interleukin - 39 in rheumatoid arthritis patients from Iraq","volume":"42","author":"Mohammed","year":"2022","journal-title":"Biomedicine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00640-x","article-title":"Emerging role of interleukin-38 (IL-38) in the development of rheumatoid arthritis","volume":"11","author":"Liang","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2022.00773","article-title":"The use of animal models in rheumatoid arthritis research","volume":"40","author":"Kong","year":"2023","journal-title":"J Yeungnam Med Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-017-0001-8","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets","volume":"1","author":"Alunno","year":"2017","journal-title":"BMC Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:41:46Z","timestamp":1776055306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1810466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1810466"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1810466","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1810466"}}